Cadila gets FDA warning for violating standards at two plants

The company said that it is working on responding to the FDA concerns

Cadila Healthcare Ltd said it had received a "warning letter" from the US Food and Drug Administration for violating manufacturing standards at two of its production sites in India, sending its shares down 15% on Thursday.

The company said its Moraiya and Ahmedabad facilities have been cited in the letter, and it is working on responding to the FDA concerns regarding the sites.

None of Cadila's products being sold in the United States use any raw materials made at the Ahmedabad plant, it added.